CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.
作者信息
Schiano di Cola Francesca, Caratozzolo Salvatore, Bolchini Marco, Ceccardi Giulia, Cortinovis Matteo, Liberini Paolo, Padovani Alessandro, Rao Renata
机构信息
Clinical and Experimental Sciences Department, Neurology Unit, University and SpedaliCivili, Brescia, Italy.
Clinical and Experimental Sciences, Università Degli Studi Di Brescia, ASST Spedali Civili Brescia, Piazzale Spedali Civili, 1, 25123, Brescia, Brescia (BS), Italy.
出版信息
Neurol Sci. 2022 Sep;43(9):5763-5764. doi: 10.1007/s10072-022-06154-0. Epub 2022 May 26.
Abstract
摘要
相似文献
1
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.降钙素基因相关肽单克隆抗体用于治疗难治性慢性偏头痛患者
Neurol Sci. 2022 Sep;43(9):5763-5764. doi: 10.1007/s10072-022-06154-0. Epub 2022 May 26.
2
Erenumab in the treatment of migraine.erenumab用于偏头痛的治疗。
Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21.
3
Migraine therapeutics differentially modulate the CGRP pathway.偏头痛治疗药物对 CGRP 通路具有差异化调节作用。
Cephalalgia. 2021 Apr;41(5):499-514. doi: 10.1177/0333102420983282. Epub 2021 Feb 24.
4
Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?抗降钙素基因相关肽（CGRP）单克隆抗体在发作性偏头痛预防中的作用：我们目前的进展如何？
Neurol India. 2021 Mar-Apr;69(Supplement):S59-S66. doi: 10.4103/0028-3886.315997.
5
Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.抗降钙素基因相关肽（CGRP）和抗 CGRP 受体单克隆抗体作为偏头痛治疗药物。基于病理生理学假说推测其安全性特征存在潜在差异。
Peptides. 2019 Jun;116:16-21. doi: 10.1016/j.peptides.2019.04.012. Epub 2019 Apr 21.
6
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.降钙素基因相关肽（CGRP）靶向单克隆抗体和拮抗剂在偏头痛中的应用：当前证据和原理。
BioDrugs. 2022 May;36(3):341-358. doi: 10.1007/s40259-022-00530-0. Epub 2022 Apr 27.
7
Treatment of migraine with monoclonal antibodies.偏头痛的单克隆抗体治疗。
Expert Opin Biol Ther. 2022 Jun;22(6):707-716. doi: 10.1080/14712598.2022.2072207. Epub 2022 May 13.
8
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study.偏头痛单克隆抗体针对 CGRP 会根据配体或受体靶点改变大脑活动 - fMRI 研究。
Elife. 2022 May 23;11:e77146. doi: 10.7554/eLife.77146.
9
Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.降钙素基因相关肽拮抗剂在偏头痛预防中的应用：关键性研究亮点及该新药类别的临床意义。
Ann Pharmacother. 2020 Aug;54(8):795-803. doi: 10.1177/1060028020903417. Epub 2020 Feb 5.
10
[Migraine preventive treatment: monoclonal antibodies against calcitonine gene related peptide].[偏头痛预防性治疗：抗降钙素基因相关肽单克隆抗体]
Medicina (B Aires). 2021;81(3):427-431.
引用本文的文献
1
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine.肉毒杆菌毒素 A：慢性偏头痛患者先前的预防性治疗可能会改善后续抗降钙素基因相关肽单克隆抗体的反应。
Toxins (Basel). 2023 Nov 30;15(12):677. doi: 10.3390/toxins15120677.
2
Photophobia and migraine outcome during treatment with galcanezumab.加卡奈珠单抗治疗期间的畏光和偏头痛结局
Front Neurol. 2023 Jan 18;13:1088036. doi: 10.3389/fneur.2022.1088036. eCollection 2022.
本文引用的文献
1
Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study.在 COVID-19 大流行封锁期间锁定 CGRP 通路：PandeMig 研究。
Neurol Sci. 2020 Dec;41(12):3385-3389. doi: 10.1007/s10072-020-04767-x. Epub 2020 Oct 1.
2
Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study.依瑞奈尤单抗治疗既往使用五种一线口服预防性药物及A型肉毒毒素治疗失败的慢性偏头痛患者：一项双中心回顾性观察研究。
Front Neurol. 2020 May 28;11:417. doi: 10.3389/fneur.2020.00417. eCollection 2020.
3
Adherence to oral migraine-preventive medications among patients with chronic migraine.慢性偏头痛患者对口服偏头痛预防性药物的依从性。
Cephalalgia. 2015 May;35(6):478-88. doi: 10.1177/0333102414547138. Epub 2014 Aug 27.
Zotero 插件